Adocia (LTS:0QAI) Payments of Debt: €-3.11 Mil (TTM As of Dec. 2025)


LTS:0QAI Adocia LTS:0QAI
44 GF Score
Price €3.96
GF Value €0.89
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Adocia Payments of Debt?

Adocia LTS:0QAI -6.07% 44 Payments of Debt is €-3.11 Mil as of Dec. 2025. GuruFocus rates LTS:0QAI with a GF Score™ of 44/100 and a GF Value™ of €0.89 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Adocia's Payments of Debt for the six months ended in Dec. 2025 was €-1.57 Mil.

Adocia's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.11 Mil.

Adocia Payments of Debt Related Terms

Adocia Payments of Debt Historical Data

* Premium members only.

The historical data trend for Adocia's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adocia Payments of Debt Chart

Adocia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.40 -10.61 -11.72 -1.64 -3.11

Adocia Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.87 -0.21 -1.43 -1.54 -1.57
LTS:0QAI
44GF Score
Adocia LTS:0QAI
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adocia Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-3.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-3.11 Mil mean?
Adocia (LTS:0QAI) has a Payments of Debt of €-3.11 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Adocia and its competitors.
Is Adocia's Payments of Debt too high?
Adocia's current Payments of Debt is €-3.11 Mil. Overall, Adocia has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adocia's Payments of Debt compare to VRTX and REGN?
Adocia's Payments of Debt of €-3.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Adocia and its competitors. Adocia's current Payments of Debt is €-3.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adocia stock overvalued right now?
Based on GuruFocus' analysis, Adocia (LTS:0QAI) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.89, compared to a current price of €3.96 — trading 344.7% above its estimated fair value. The current Payments of Debt is €-3.11 Mil. Adocia's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Adocia (LTS:0QAI), the current Payments of Debt is €-3.11 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adocia (LTS:0QAI) Overvalued in 2026?

Based on GuruFocus' analysis, Adocia stock appears to be overvalued. The current stock price of €3.96 is trading 344.7% above its estimated GF Value™ of €0.89. GuruFocus considers Adocia to be Significantly Overvalued.

Key valuation signals for LTS:0QAI:

  • Payments of Debt: €-3.11 Mil
  • GF Value™: €0.89 vs. price of €3.96 (344.7% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the LTS:0QAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adocia Business Description

Other Exchanges ADOC:FranceA89:Germany
Address 115 Avenue Lacassagne, Lyon, FRA, 69003
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
44GF Score

Get the complete analysis for LTS:0QAI

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.96
Price
€0.89
GF Value